Genomictree Inc. Total Liabilities
Genomictree Inc. total liabilities. Based on the latest financial reports, Genomictree Inc. (228760) has total liabilities worth ₩5.45 Billion KRW (≈ $3.69 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Genomictree Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Genomictree Inc. (2020–2025)
Total liabilities of Genomictree Inc. from 2020 to 2025. This chart illustrates how Genomictree Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Genomictree Inc. Competitors by Total Liabilities
The table below lists competitors of Genomictree Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
Turkey | TL1.88 Billion |
|
Mainstreet Bank
NASDAQ:MNSB
|
USA | $2.01 Billion |
|
Ecomate Holdings Bhd
KLSE:0239
|
Malaysia | RM65.68 Million |
|
Electreon Wireless Ltd
TA:ELWS
|
Israel | ILA23.94 Million |
|
eCloudvalley Digital Technology Co. Ltd.
TW:6689
|
Taiwan | NT$3.08 Billion |
|
Cadence Capital Ltd
AU:CDM
|
Australia | AU$77.57 Million |
|
Whitestone Group
BR:ROCK
|
Belgium | €410.99K |
|
Evolution Petroleum Corporation Inc
NYSE MKT:EPM
|
USA | $101.72 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Genomictree Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Genomictree Inc. asset portfolio.
Liquidity & Leverage Metrics
Genomictree Inc. Total Liabilities Ratios Explained
Genomictree Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomictree Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomictree Inc. (2020–2025)
The table below shows the annual total liabilities of Genomictree Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩5.45 Billion ≈ $3.69 Million |
-14.22% |
| 2024-12-31 | ₩6.36 Billion ≈ $4.31 Million |
-18.64% |
| 2023-12-31 | ₩7.81 Billion ≈ $5.29 Million |
-86.01% |
| 2022-12-31 | ₩55.86 Billion ≈ $37.85 Million |
-9.98% |
| 2021-12-31 | ₩62.05 Billion ≈ $42.05 Million |
+174.07% |
| 2020-12-31 | ₩22.64 Billion ≈ $15.34 Million |
-- |
About Genomictree Inc.
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect … Read more